Biotech Values

[FreeNorth]

Re: JAK inhibitors associated with increased risk of lymphoma

The article in Blood is less definitive than that news report. See page 13 of the PDF of the article:

While all four of our lymphoma patients were treated with ruxolitinib, one patient had initially been treated with another selective JAK2 inhibitor, fedratinib. It remains to be determined whether lymphoma development is restricted to ruxolitinib treated patients or constitutes a general phenomenon upon JAK1/2 inhibition. Moreover, it remains unclear whether lymphomagenesis is predominantly associated with JAK1 or JAK2 inhibition, or both